Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gastroenterology

• Publication date

  2016-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2016.05.004PMID 27210037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice

  2016cited by this paper
• Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients.

  2015cited by this paper
• Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

  2015cited by this paper
• Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy

  2015cited by this paper
• European cancer mortality predictions for the year 2014.

  2014cited by this paper
• Pancreatic adenocarcinoma.

  2014cited by this paper
• Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

  2014cited by this paper
• The Impact of Neural Invasion Severity in Gastrointestinal Malignancies: A Clinicopathological Study

  2014cited by this paper
• Pancreatic adenocarcinoma.

  2014cited by this paper
• Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

  2014cited by this paper
• Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

  2014cited by this paper
• Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy

  2014cited by this paper
• SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.

  2013cited by this paper
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

  2013cited by this paper
• Advanced-stage pancreatic cancer: therapy options

  2013cited by this paper
• Adjuvant gemcitabine therapy improves survival in a locally induced, R0‐resectable model of metastatic intrahepatic cholangiocarcinoma

  2013cited by this paper
• Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

  2012cited by this paper
• Only women with symptoms need to have their breast implants removed, says government

  2012cited by this paper
• Nerve-Cancer Interactions in the Stromal Biology of Pancreatic Cancer

  2012cited by this paper
• Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

  2012cited by this paper
• Perineural invasion and associated pain in pancreatic cancer

  2011cited by this paper
• Pancreatic cancer

  2011cited by this paper
• Pancreatic cancer.

  2010cited by this paper
• The Severity of Neural Invasion Is a Crucial Prognostic Factor in Rectal Cancer Independent of Neoadjuvant Radiochemotherapy

  2010cited by this paper
• Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

  2010cited by this paper
• TLR4/MyD88-Induced CD11b+Gr-1intF4/80+ Non-Migratory Myeloid Cells Suppress Th2 Effector Function in the Lung

  2010cited by this paper
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

  2009cited by this paper
• A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

  2009cited by this paper
• Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF

  2009cited by this paper
• Epidemiology of pancreatic cancer: an overview

  2009cited by this paper
• Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial

  2008cited by this paper
• Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

  2007cited by this paper
• Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

  2007cited by this paper
• Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.

  2007cited by this paper
• Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

  2007cited by this paper
• Genetics and biology of pancreatic ductal adenocarcinoma.

  2006cited by this paper
• Pancreatic adenocarcinoma

  2006cited by this paper
• Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

  2006cited by this paper
• Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

  2003cited by this paper
• Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

  1998cited by this paper

• Characterization of single neurons reprogrammed by pancreatic cancer

  2025cites this paper
• SMAD4 and KRAS Status Shape Cancer Cell-Stromal Crosstalk and Therapeutic Response in Pancreatic Cancer

  2025cites this paper
• Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Using Infusional Gemcitabine: Immune Cell Infiltration Analysis and Updated Survival

  2025cites this paper
• Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial

  2025cites this paper
• Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition

  2025cites this paper
• Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas

  2025cites this paper
• Surgical Resection of Murine PDAC Alters Hepatic Metastases and Immune Microenvironment.

  2025cites this paper
• Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells

  2024cites this paper
• Evaluating the benefits of adjuvant chemotherapy in patients with pancreatic cancer undergoing radical pancreatectomy after neoadjuvant therapy—a systematic review and meta-analysis

  2024cites this paper
• Membrane-immobilized gemcitabine for cancer-targetable NK cell surface engineering.

  2024cites this paper
• Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation

  2024cites this paper
• First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis.

  2024cites this paper
• Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer

  2024cites this paper
• Syringeable Near-Infrared Light-Activated In Situ Immunogenic Hydrogel Boosts the Cancer-Immunity Cycle to Enhance Anticancer Immunity.

  2024cites this paper
• The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer

  2024influential citation
• Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies

  2024cites this paper
• The causal effects of immune cells on pancreatic cancer: A 2‑sample Mendelian randomization study

  2024cites this paper
• Modelling the micro- and macro- environment of pancreatic cancer: from patients to pre-clinical models and back

  2024cites this paper
• Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies

  2024cites this paper
• Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study

  2024cites this paper
• Advances in Making Cancer Mouse Models More Accessible and Informative through Non-Germline Genetic Engineering.

  2023cites this paper
• Identification of TRDV-TRAJ V domains in human and mouse T-cell receptor repertoires

  2023cites this paper
• Gemcitabine effects on tumor microenvironment of pancreatic cancer: Special focus on resistance mechanisms and metronomic therapies.

  2023cites this paper
• Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer

  2023cites this paper
• Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer

  2023cites this paper
• Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis

  2022cites this paper
• NK cells and solid tumors: therapeutic potential and persisting obstacles

  2022cites this paper
• Regulatory T Cells in Pancreatic Cancer: Of Mice and Men

  2022cites this paper
• Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro

  2022cites this paper
• The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)

  2022cites this paper
• Innate Lymphoid Cells: Emerging Players in Pancreatic Disease

  2022cites this paper
• Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer

  2022cites this paper
• CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver

  2022cites this paper
• Four drug metabolism-related subgroups of pancreatic adenocarcinoma in prognosis, immune infiltration, and gene mutation

  2022cites this paper
• High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer

  2022cites this paper
• Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment

  2022cites this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• Mouse Models to Study Secondary Cancer Prevention.

  2022cites this paper
• Tumour microenvironment and heterotypic interactions in pancreatic cancer

  2022cites this paper
• CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice

  2021cites this paper
• Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• Oxygen-Delivering Polyfluorocarbon Nanovehicles Improve Tumor Oxygenation and Potentiate Photodynamic-Mediated Antitumor Immunity.

  2021cites this paper
• Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy

  2021cites this paper
• UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy

  2021cites this paper
• Modeling pancreatic cancer in mice for experimental therapeutics.

  2021cites this paper
• The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

  2021cites this paper
• Application of natural killer cells in pancreatic cancer.

  2021cites this paper
• Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment

  2021cites this paper
• Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment

  2021cites this paper
• The Neglected Liaison: Targeting Cancer Cell Metabolic Reprogramming Modifies the Composition of Non-Malignant Populations of the Tumor Microenvironment

  2021cites this paper
• In vivo Mouse Models of Pancreatic Ductal Adenocarcinoma

  2021influential citation
• The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer

  2020cites this paper
• Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.

  2020cites this paper
• Tumor-permeated bioinspired theranostic nanovehicle remodels tumor immunosuppression for cancer therapy.

  2020cites this paper
• Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation

  2020cites this paper
• Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection

  2020cites this paper
• Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives.

  2020cites this paper
• The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC

  2020cites this paper
• The Immune Microenvironment in Pancreatic Cancer

  2020cites this paper
• Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine

  2020cites this paper
• Regulation and modulation of antitumor immunity in pancreatic cancer

  2020cites this paper
• PAF1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions with PHF5A and DDX3.

  2020cites this paper
• Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer

  2020cites this paper
• Localisation analysis of nerves in the mouse pancreas reveals the sites of highest nerve density and nociceptive innervation

  2020cites this paper
• An Immunological Glance on Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Black raspberries suppress pancreatic cancer through modulation of NKp46+, CD8+, and CD11b+ immune cells.

  2020cites this paper
• Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment

  2020cites this paper
• An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma

  2020cites this paper
• 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer

  2019cites this paper
• Tumor-derived exosomes inhibit natural killer (NK) cell functions in the pre-metastatic niche of pancreatic cancer

  2019cites this paper
• Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells

  2019cites this paper
• Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer

  2019cites this paper
• Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.

  2019cites this paper
• Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma

  2019cites this paper
• Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients

  2019cites this paper
• Exploring signaling pathways and pancreatic cancer treatment approaches using genetic models.

  2019cites this paper
• Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive In Vitro Analysis on Patient-Derived Tumor Models

  2019cites this paper
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

  2019cites this paper
• Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review

  2018cites this paper
• Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma

  2018cites this paper
• Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

  2018cites this paper
• Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers

  2017cites this paper
• Chemotherapy agent‐unsaturated fatty acid prodrugs and prodrug‐nanoplatforms for cancer chemotherapy

  2017cites this paper
• Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

  2016cites this paper
• Myeloid-derived suppressor cells and their role in pancreatic cancer

  2016cites this paper